ARTICLE | Clinical News
Merck's cilengitide misses in Phase III for glioblastoma multiforme
February 26, 2013 1:32 AM UTC
The EMD Serono Inc. subsidiary of Merck KGaA (Xetra:MRK) said twice-weekly IV cilengitide plus standard radiation and Temodar temozolomide therapy missed the primary endpoint of improving overall survival (OS) vs. radiation and temozolomide alone in the Phase III CENTRIC trial to treat glioblastoma multiforme (GBM). The open-label, international trial enrolled more than 500 newly diagnosed GBM patients with methylated O6-methylguanine- DNA methyltransferase ( MGMT) gene promoter status. The trial was conducted in partnership with the European Organization for Research and Treatment of Cancer (EORTC). ...